Back to News
Market Impact: 0.38
AC Immune Posts Positive Week 100 Phase 2 Data For ACI-7104 In Parkinson's Disease; Stock Up
Source: Nasdaq
Healthcare & BiotechProduct Launches
AC Immune reported positive Week-100 results from Part 1 of its Phase 2 VacSYn trial of ACI-7104 in patients with early-stage Parkinson's disease. The long-duration positive clinical update supports continued development of the vaccine candidate and is a favorable catalyst for AC Immune shares.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.58
Ticker Sentiment
ACIU0.82
More News
- OpenAI’s agent hacked Australia’s Medicare website—the latest rogue AI incident that the company didn’t know about for months
- Meta announces new lightweight virtual reality glasses to one-up Apple’s Vision Pro
- How Meta took the lead in the race for the post-smartphone world
- Australia says OpenAI agent hacked Medicare portal
- Mark Zuckerberg debuts $1,299 Meta VR Glasses and Muse Charm pendant amid AI agent push
- Meta's standoff with Amazon over Muse could be a sign of things to come